United States · FDA National Drug Code directory
Mirvaso
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0299-5980_253bf4a2-3c4d-f4af-e063-6394a90a0b0a
- Product NDC
- 0299-5980
- Form
- GEL
- Composition / generic term
- brimonidine tartrate
- Labeler
- Galderma Laboratories, L.P.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20130823
- Source listing expiry
- 20261231
Source-listed ingredients
- BRIMONIDINE TARTRATE — 5 mg/g
These values do not establish equivalence or a dose recommendation.
Packages
- 1 TUBE in 1 BLISTER PACK (0299-5980-00) / 2 g in 1 TUBE · 0299-5980-00
- 2 g in 1 TUBE (0299-5980-02) · 0299-5980-02
- 30 g in 1 TUBE (0299-5980-30) · 0299-5980-30
- 1 BOTTLE, PUMP in 1 CARTON (0299-5980-35) / 30 g in 1 BOTTLE, PUMP · 0299-5980-35
- 45 g in 1 TUBE (0299-5980-45) · 0299-5980-45
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →